AAVXF:OTCMKTS
Abivax SA
139,00 $
0,00%
(0,00) 1 d.
9. jūl., 09:30:01 GMT-4 · USD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: AAVXF…
Tirgus kapitalizācija
6,63 mljrd.
Vid. apjoms
0,00
Apjoms
0,00
Augstākā 52 ned.
139,00 $
Zemākā 52 ned.
71,26 $
Beta
3,09
Apgrozībā esošās akcijas
87,53 milj.
Darbinieku skaits
98
Tirgus kapitalizācija
6,63 mljrd.
Vid. apjoms
0,00
Apjoms
0,00
Augstākā 52 ned.
139,00 $
Zemākā 52 ned.
71,26 $
Beta
3,09
Apgrozībā esošās akcijas
87,53 milj.
Darbinieku skaits
98
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
https://www.dars.gov.et/
·
pirms 5 dienām
ABVX Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Keeps Spending on Pipeline
Profils
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Par “Abivax SA”
ĢenerāldirektorsMarc de Garidel | Hartmut J. Ehrlich
Darbinieki98
Dibināšanas datums2013. gada 4. dec.
Galvenais birojs-
Sektors-
Tīmekļa vietneabivax.com